/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a.
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 673,000 shares, a growth of 25.4% from the August 31st total of 536,500 shares. Based on an average daily trading volume, of 609,800 […]
Here are some of Wednesday’s biggest movers: Cardiff Oncology Inc. CRDF, shares surged 32% on favorable data from two cancer drug trials metastatic…